Literature DB >> 14639052

Dose-adjusted cyclosporine c2 in a patient with jejunoileal bypass as compared to seven other liver transplant recipients.

Rou-Yee Chenhsu1, Youmin Wu, Daniel Katz, Stephen Rayhill.   

Abstract

Jejunoileal bypass (JIB) is a weight loss procedure in which malabsorption is produced by connecting a short length of proximal jejunum to the distal ileum. Because 90% of the small intestine is bypassed, it may have impact on the dose-concentration response of oral cyclosporine (CsA). The authors characterized the dose-adjusted blood concentrations of CsA obtained 2 hours (C2) after oral microemulsion CsA (ME-CsA) in a liver transplant (LTx) subject with an intact JIB, as compared with those from seven LTx controls without JIB. The biliary reconstruction involved choledochocholedochostomy without external drainage in all patients. ME-CsA was administered via a nasogastric tube within 24 hours after graft reperfusion. Oral fluconazole was given prophylactically to the study subject only for 6 days after LTx. During the first week after LTx, the dose-adjusted C2 (mean +/- SD) for the study subject and for controls was 53 +/- 10 and 106 +/- 47 ng/mL, respectively (P < 0.001). The corresponding value during the period from day 7 to day 107 was 105 +/- 40 and 257 +/- 86 ng/mL, respectively (P < 0.001). Multiple linear regression revealed that dosage, days after LTx, and the presence of a JIB were all independent predictors of C2 (R2 = 0.798, P = 0.037). Lack of bile resulting in malabsorption of ME-CsA was not thought to be significant contributor to her low dose-adjusted C2 because there was no external bile drainage and a portion of terminal ileum, where most bile acid reabsorption occurred, was still available after JIB. The fact that fluconazole failed to increase the dose-adjusted C2 in the study subject supports that enteric clearance of CsA may become clinically unimportant after JIB. Therefore, the low dose-adjusted C2 is most likely explained by the reduced bowel length and associated absorptive surface area after JIB. In conclusion, patients with JIB may require higher doses of ME-CsA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14639052     DOI: 10.1097/00007691-200312000-00004

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  9 in total

Review 1.  Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes.

Authors:  Adam S Darwich; Kathryn Henderson; Angela Burgin; Nicola Ward; Janet Whittam; Basil J Ammori; Darren M Ashcroft; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

2.  Systematic review of drug bioavailability following gastrointestinal surgery.

Authors:  Manuela Moreno Santamaría; José Javier Arenas Villafranca; Jimena Abilés; Alberto Fernández López; Lucia Visiedo Rodas; Begoña Tortajada Goitia; Pilar Utrilla Navarro
Journal:  Eur J Clin Pharmacol       Date:  2018-08-22       Impact factor: 2.953

Review 3.  Vitamin, mineral, and drug absorption following bariatric surgery.

Authors:  Ronald Andari Sawaya; Jane Jaffe; Lindsay Friedenberg; Frank K Friedenberg
Journal:  Curr Drug Metab       Date:  2012-11       Impact factor: 3.731

4.  Lithium toxicity after Roux-en-Y bariatric surgery.

Authors:  Deanna Musfeldt; Andrew Levinson; Jennifer Nykiel; Gerardo Carino
Journal:  BMJ Case Rep       Date:  2016-03-18

5.  Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study.

Authors:  Christin C Rogers; Rita R Alloway; J Wesley Alexander; Michael Cardi; Jennifer Trofe; Alexander A Vinks
Journal:  Clin Transplant       Date:  2008 May-Jun       Impact factor: 2.863

6.  Evaluation of an In Silico PBPK Post-Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine.

Authors:  A S Darwich; D Pade; K Rowland-Yeo; M Jamei; A Asberg; H Christensen; D M Ashcroft; A Rostami-Hodjegan
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-06-12

Review 7.  Nanotechnology as a tool to overcome the bariatric surgery malabsorption.

Authors:  Osaid Almeanazel; Fars Alanazi; Ibrahim Alsarra; Doaa Alshora; Faiyaz Shakeel; Ahmad Almnaizel; Mohammed Alahmed; Ehab Fouad
Journal:  Saudi Pharm J       Date:  2020-03-19       Impact factor: 4.330

Review 8.  Drug absorption in bariatric surgery patients: A narrative review.

Authors:  Abdullah Abdulaziz Alalwan; Jeffrey Friedman; Osamah Alfayez; Abraham Hartzema
Journal:  Health Sci Rep       Date:  2022-04-26

9.  Changes of Drug Pharmacokinetics in Patients with Short Bowel Syndrome: A Systematic Review.

Authors:  Wallace Bok-Thoe Hong; Wee Kiat Tan; Lawrence Siu-Chun Law; David Eng-Hui Ong; Elaine Ah-Gi Lo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-07-01       Impact factor: 2.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.